ARKG is an actively managed fund that targets companies involved in the genomics industry.
FDA panel approves expanded use of peptides in compounding pharmacies, raising concerns about prescription surge in billion-dollar industry.
Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine
Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a "Market Misread"
TEM: $1.5B acquisition combines MRD portfolios to drive growth, data synergies, and profitability by 2027
TEM: A $1.5B acquisition merges AI oncology and MRD tech to lead in cancer monitoring